Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06130787

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Led by University Hospital, Clermont-Ferrand · Updated on 2024-09-27

321

Participants Needed

17

Research Sites

261 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

CONDITIONS

Official Title

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Chronic phase chronic myeloid leukemia diagnosed no more than 3 months prior to inclusion
  • Diagnosis confirmed by Philadelphia chromosome (Ph1) or FISH for cryptic Ph1
  • BCR-ABL1 transcript quantifiable by quantitative PCR
  • First-line treatment with tyrosine kinase inhibitor
  • No prior tyrosine kinase inhibitor or hydroxyurea treatment before first blood sampling
  • Signed informed consent for CML Observatory and BIO-TIMER protocol
  • Able to read and understand French
  • Enrolled in or beneficiary of a social security plan
Not Eligible

You will not qualify if you...

  • CML in accelerated or blast phase
  • Refusal to participate in the study
  • Treatment started prior to inclusion
  • Under guardianship, curatorship, deprivation of liberty, or safeguard of justice
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

CHU Annecy-Genevois

Annecy, France

Actively Recruiting

2

Institut Bergonié

Bordeaux, France

Not Yet Recruiting

3

CHU Caen

Caen, France

Actively Recruiting

4

CHU de Clermont-Ferrand

Clermont-Ferrand, France, 63000

Actively Recruiting

5

CHU Créteil

Créteil, France

Not Yet Recruiting

6

CHU Grenoble Alpes

Grenoble, France

Not Yet Recruiting

7

Centre Hospitalier Emile Roux

Le Puy-en-Velay, France

Actively Recruiting

8

CHRU Lille

Lille, France

Not Yet Recruiting

9

CHU Limoges

Limoges, France

Actively Recruiting

10

Centre Léon Bérard

Lyon, France

Withdrawn

11

Institut Paoli-Calmettes

Marseille, France

Actively Recruiting

12

CHU Nancy

Nancy, France

Actively Recruiting

13

Groupe Hospitalier Paris Saclay - Site de Bicêtre

Paris, France

Actively Recruiting

14

CHU Rennes

Rennes, France

Actively Recruiting

15

CHU Saint-Etienne

Saint-Etienne, France

Actively Recruiting

16

Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse, France

Actively Recruiting

17

CHU Versailles

Versailles, France

Actively Recruiting

Loading map...

Research Team

L

Lise LACLAUTRE

CONTACT

M

Mélanie CASILE, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy | DecenTrialz